ASXC — Asensus Surgical Share Price
0.000.00%
Last trade - 00:00- $81.58m
- $89.11m
- $8.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -334.02% | ||
| Operating Margin | -857.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.53 | 3.17 | 8.23 | 7.09 | 8.58 | 12.06 | 21.91 | -18.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Asensus Surgical, Inc. is a medical device company digitizing the interface between the surgeon and patient to reimagine surgery through Performance-Guided Surgery to enable surgeons to deliver outcomes to patients and establish a new standard of surgery. It operates in one business segment, which is the research, development and sale of medical device robotics to improve minimally invasive surgery. It is developing the LUNA Surgical System, a robotic and instrument system as a foundation of its Digital Surgery solution. These systems shall be powered by the Intelligent Surgical Unit to enhance surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, it intends to holistically address the clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. It is also working to incorporate all of this in the LUNA Surgical System.
Directors
- David Milne CHM (58)
- Anthony Fernando PRE (49)
- Shameze Rampertab CFO (54)
- Andrea Biffi IND (39)
- Kevin Hobert IND (55)
- Jane Hsiao IND (74)
- Elizabeth Kwo IND (40)
- Richard Pfenniger IND (65)
- William Starling IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 19th, 1988
- Public Since
- August 6th, 1991
- No. of Shareholders
- 67
- No. of Employees
- 207
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 272,842,574
- Address
- 1 TW ALEXANDER DRIVE, SUITE 160, DURHAM, 27703
- Web
- https://asensus.com/
- Phone
- +1 9197658400
- Auditors
- BDO USA, P.C.
Upcoming Events for ASXC
Similar to ASXC
Acme United
NYSE MKT
Alpha Pro Tech
NYSE MKT
Catheter Precision
NYSE MKT
Electromed
NYSE MKT
Infusystem Holdings
NYSE MKT
FAQ
What is the Asensus Surgical share price?
As of Today at 23:18 UTC, shares in Asensus Surgical are trading at $0.30. This share price information is delayed by 15 minutes.
How has the Asensus Surgical share price performed this year?
Shares in Asensus Surgical last closed at $0.30 and the price had moved by +2.05% over the past 365 days. In terms of relative price strength the Asensus Surgical share price has underperformed the S&P500 Index by -19.94% over the past year.
What are the analyst and broker recommendations for Asensus Surgical?
The overall consensus recommendation for Asensus Surgical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Asensus Surgical dividend yield?
Asensus Surgical does not currently pay a dividend.
Does Asensus Surgical pay a dividend?
Asensus Surgical does not currently pay a dividend.
When does Asensus Surgical next pay dividends?
Asensus Surgical does not currently pay a dividend.
How do I buy Asensus Surgical shares?
To buy shares in Asensus Surgical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Asensus Surgical?
As of the previous close price of $0.30, shares in Asensus Surgical had a market capitalisation of $81.58m.
Where are Asensus Surgical shares listed?
Here are the trading details for Asensus Surgical:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: ASXC
What kind of share is Asensus Surgical?
Based on an overall assessment of its quality, value and momentum Asensus Surgical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Asensus Surgical share price forecast for 2024?
The analyst consensus target price for shares in Asensus Surgical is $0.35. That is 17.06% above the last closing price of $0.30.
Analysts covering Asensus Surgical currently have a consensus Earnings Per Share (EPS) forecast of -$0.24 for the next financial year.
Find out moreWhat is the trend in the Asensus Surgical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Asensus Surgical. Over the past six months, its share price has underperformed the S&P500 Index by -6.48%.
As of the last closing price of $0.30, shares in Asensus Surgical were trading +4.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Asensus Surgical PE Ratio?
The Asensus Surgical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Asensus Surgical?
Asensus Surgical's management team is headed by:
- David Milne - CHM
- Anthony Fernando - PRE
- Shameze Rampertab - CFO
- Andrea Biffi - IND
- Kevin Hobert - IND
- Jane Hsiao - IND
- Elizabeth Kwo - IND
- Richard Pfenniger - IND
- William Starling - IND